- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07573098
Digital Tool for Improved Self-management of COPD (FOCUS)
Primary aim: To evaluate the feasibility, usability and safety of the investigational device in clinical practice over 6 months in 50 patients.
Secondary aims: To describe the number of healthcare contacts and the adequacy of those contacts.
Study design: Traditional feasibility clinical investigationPilot feasibility open observational study.
Subjects: 50 subjects being investigated for or with a diagnosis of COPD with at least one exacerbation within the last year will be invited to voluntarily participate. Exclusion criteria is severe disease from either COPD or any severe concomitant conditions that would make home spirometry unsafe for the patient. Patients with no access to use BankID or similar electronic personal identification service and not using Android (version 8+) or iOS (version 16+) smartphones will be excluded.
Intervention: At inclusion patients will be on-boarded on to the digital platform and recommended to follow instructions in the app. The intervention is the COPD Treatment check, which is a medical device that is connected to a spirometer. Patients will be instructed to self-test on a daily basis.
Control group: There will be no control group.
Primary endpoints:
• Feasability and usability of the system in a clinical setting as determined by usage and questionnaire evaluation. Feasibility measured by proportion of participants who complete the study, compliance and adoption (system usage), time needed to train users
Secondary endpoints:
Safety of the device
- Experienced usability and the number of adverse events
Adequacy of the participant's healthcare contacts.
- Number of actual clinic contacts in relation to the number of recommendations by the COPD treatment check to seek medical attention. Exacerbations (as defined by healthcare staff)
- Evaluation of questionnaires (healthcare and patient reported)
Panoramica dello studio
Descrizione dettagliata
Patient "education" often takes the form of providers giving didactic Information and assumes that knowledge will lead to behavioural change. Although important, it may not be sufficient for promoting self-management skills. Enhancing patient knowledge is an important step towards behaviour change using self-management interventions and should include topics such as smoking cessation, correct use of inhaler devices, early recognition of exacerbations, decision-making and acting at the right time, and when to seek help. Personalized education and training that takes into account specific issues relating to the individual patient, and that aims to enhance long-term functionality and appropriate health behaviours are likely to benefit patients more. A good COPD self-management intervention is structured but personalized, with goals of motivating, engaging and supporting the patients to positively adapt their health behaviour(s) and develop skills to better manage their disease. The aim is to elicit patient motivation, confidence and competence. Systematic reviews have provided evidence that self-management interventions improve outcomes in COPD. A 2022 Cochrane review reported that interventions for people with COPD are associated with improvements in health-related quality of life (HRQoL), a lower probability of respiratory-related hospital admissions, and no excess respiratory-related and all-cause mortality risks.
One of the most important goals for treatment of COPD exacerbations are to minimize the negative impact of an exacerbation and to prevent subsequent events. Also, it is now recognized that many exacerbations are not reported to healthcare professionals for therapy and yet these events have a significant impact on health status. Thus, one focus is for COPD patients to receive education about the importance of understanding exacerbation symptoms and when to seek professional healthcare.
According to the Swedish National Board of Health and Welfare a written self-management plan should be established together with the healthcare team and be reevaluated at follow-up visits. The plan should contain information on how to adjust treatment according to for example symptoms and infections, and when it is important for the patient to contact healthcare for assistance.
The investigational device is a separate module, COPD Treatment check, embedded in the cloud-based CE-marked system called AsthmaTuner. Our hypothesis is that this digital tool will improve self-management of COPD. Thus, the aim of this study is to assess the feasibility, usability and safety of the COPD Treatment check in clinical practice. Secondary aim is to evaluate the number of healthcare contacts and the adequacy of those contacts.
At baseline, a trained nurse will onboard and instruct patients in device handling (standard education). According to a flow algorithm, the app will instruct patients to contact their healthcare provider. The healthcare provider will be able to see collected data that is displayed in the back-end system but will not be instructed to actively monitor patients.
Data on feasibility, safety and experienced usability of the investigational device will be presented. The analysis of feasibility and the experienced benefit of using the COPD Treatment check in clinical practice is estimated on a Likert scale from 1 (strongly disagree) to 5 (strongly agree), and presented as mean and median scores. The number of clinic contacts will be presented in relation to the number of times that the app has recommended such contacts. A medical doctor will categorize the contacts as correct or incorrect, without knowing whether the contacts were initiated via the app or the patient themselves to avoid bias.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Henrik Ljungberg
- Numero di telefono: +46706628642
- Email: henrik.ljungberg@ki.se
Luoghi di studio
-
-
Stockholm County
-
Solna, Stockholm County, Svezia, 17164
- Reclutamento
- KPE Lung and Allergy, QB:84, Karolinska University Hospital.
-
Contatto:
- Björn Nordlund Sponsor and Investigator, PhD, Associate Professor
- Numero di telefono: 0046703234414
- Email: bjorn.nordlund@ki.se
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Subjects from the age of 40 years with documented diagnosis of COPD, using at least two inhaled medications (one combination inhaler or several inhalers), and with at least one exacerbation within the last year will be invited to voluntarily participate.
Exclusion Criteria:
- Exclusion criteria is severe disease from either COPD or any severe concomitant conditions that would make home spirometry unsafe for the patient. Patients with no access to use BankID or similar electronic personal identification service and not using smartphones will be excluded. Also, individuals who are pregnant or breastfeeding women, and individuals who are unable to provide informed consent due to cognitive impairment or other reasons indicating lack of decision-making capacity will be excluded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: COPD treatment check
At inclusion patients will be onboarded to the digital platform and recommended to follow instructions in the app.
The intervention is the COPD Treatment check, which is a medical device that is connected to a spirometer.
Patients will be instructed to self-test on a daily basis.
|
The investigational device is designed to support self-management of COPD.
It provided patients with remote individualized feedback and recommendations for symptom relief and exacerbation management based on actual lung function and symptom report.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The rate of participants that perceives the device feasible to use.
Lasso di tempo: 6 months
|
Feasability of the system in a clinical setting as determined by usage and questionnaire evaluation.
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adequacy of the participant's healthcare contacts and adverse events.
Lasso di tempo: 6 months
|
Number of actual clinic contacts in relation to the number of recommendations by the COPD treatment check to seek medical attention.
Adverse events listed in agreement with the Clinical Investigation Plan version 5.
|
6 months
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55. doi: 10.1164/rccm.200703-456SO. Epub 2007 May 16.
- Jansson SA, Ronmark E, Forsberg B, Lofgren C, Lindberg A, Lundback B. The economic consequences of asthma among adults in Sweden. Respir Med. 2007 Nov;101(11):2263-70. doi: 10.1016/j.rmed.2007.06.029. Epub 2007 Aug 6.
- Ljungberg H, Carleborg A, Gerber H, Ofverstrom C, Wolodarski J, Menshi F, Engdahl M, Eduards M, Nordlund B. Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial. Eur Respir J. 2019 Nov 14;54(5):1900983. doi: 10.1183/13993003.00983-2019. Print 2019 Nov.
- Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017 Mar 6;49(3):1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar.
- Breckner, A., et al., Self-management perspectives of elderly patients with multimorbidity and practitioners - status, challenges and further support needed? BMC Fam Pract, 2021. 22(1): p. 238.
- Human, D., F. Crawley, and I.J. C, Revised declaration of Helsinki. WMA will continue to revise policy as medicine and research changes. BMJ, 2001. 323(7307): p. 283-4.
- Williams, V., et al., Using a mobile health application to support self-management in COPD: a qualitative study. Br J Gen Pract, 2014. 64(624): p. e392-400.
- Chau, J.P., et al., A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int J Med Inform, 2012. 81(10): p. 674-82.
- Quanjer, P.H., et al., Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J, 2012. 40(6): p. 1324-43.
- Miller, M.R., et al., Standardisation of spirometry. Eur Respir J, 2005. 26(2): p. 319-38.
- Schoultz, K., A. Svensson, and M. Emilsson, Nurses' experiences of using AsthmaTuner - an eHealth self-management system for healthcare of patients with asthma. Digit Health, 2022. 8: p. 20552076221092542.
- Regions, S.A.o.L.A.a., Treatment plan COPD. https://registercentrum.blob.core.windows.net/lvr/r/KOL-Min-behandlingsplan-S1g1JxirfL.pdf, 2024 Dec.
- Welfare, S.N.B.o.H.a., Performance assessment of asthma and COPD healthcare. https://www.socialstyrelsen.se/globalassets/sharepoint-dokument/artikelkatalog/nationella-riktlinjer/2018-12-44-eng.pdf, 2018.
- Wilkinson, T.M., et al., Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004. 169(12): p. 1298-303.
- Schrijver, J., et al., Self-management interventions for people with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2022. 1(1): p. CD002990.
- Effing, T.W., et al., Definition of a COPD self-management intervention: International Expert Group consensus. Eur Respir J, 2016. 48(1): p. 46-54.
- Riley, C.M. and F.C. Sciurba, Diagnosis and Outpatient Management of Chronic Obstructive Pulmonary Disease: A Review. JAMA, 2019. 321(8): p. 786-797.
- Cravo, A., et al., The Importance of Self-Management in the Context of Personalized Care in COPD. Int J Chron Obstruct Pulmon Dis, 2022. 17: p. 231-243.
- Organization, W.H., WHO package of essential non-communicable diseases interventions for primary health care. https://iris.who.int/bitstream/handle/10665/334186/9789240009226-eng.pdf?sequence=1.
- Miller, J., et al., Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med, 2013. 107(9): p. 1376-84.
- Parker, C.M., et al., Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J, 2005. 26(3): p. 420-8.
- Zafari, Z., et al., Projecting Long-term Health and Economic Burden of COPD in the United States. Chest, 2021. 159(4): p. 1400-1410.
- Halpin, D.M.G., et al., It is time for the world to take COPD seriously: a statement from the GOLD board of directors. Eur Respir J, 2019. 54(1).
- Mathers, C.D. and D. Loncar, Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med, 2006. 3(11): p. e442.
- Nordlund, B., et al., The clinical benefit of evaluating health-related quality-of-life in children with problematic severe asthma. Acta paediatrica, 2011. 100(11): p. 1454-60.
- Mannino, D.M., A. Sonia Buist, and W.M. Vollmer, Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax, 2007. 62(3): p. 237-41.
- World Health Organization: Chronic obstructive pulmonary disease (COPD):. [cited 2024 Dec.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CIV-24-12-050346
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su BPCO
-
Fraunhofer-Institute of Toxicology and Experimental...Institute for Pharmacology and Toxicology, RWTH AachenCompletatoVolontari sani | COPD GOLD da I a IV | Asma GINA da 1 a 4Germania
Prove cliniche su COPD treatment check
-
University of OregonNational Institute on Drug Abuse (NIDA)Reclutamento
-
University of Alabama at BirminghamNational Institute on Aging (NIA)Completato
-
University of Illinois at ChicagoNational Institute on Minority Health and Health Disparities (NIMHD); Sinai Urban...Non ancora reclutamento
-
Wayne State UniversityCompletatoGenitorialità | Comportamento dirompenteStati Uniti
-
University of OregonNational Institute on Drug Abuse (NIDA)CompletatoDepressione | Fatica | Ansia | Relazioni genitori-figli | Genitorialità | Disturbi da Uso di Sostanze | Pediatria | Autoefficacia genitorialeStati Uniti
-
Universitair Ziekenhuis BrusselNon ancora reclutamento
-
Brown UniversityCompletatoUso di sostanzeStati Uniti
-
Boston Scientific CorporationPneumRx, Inc.TerminatoSintomi della BPCO dopo la procedura di bobinaSvizzera
-
Reistone Biopharma Company LimitedCompletato
-
Seattle Children's HospitalReclutamentoComportamento adolescenzialeStati Uniti